BioCentury
ARTICLE | Finance

Refining GPCRs

VCs back Trevena's refined GPCR attack; target proof of concept in heart failure

July 19, 2010 7:00 AM UTC

Trevena Inc. secured a $35 million series B round last week to get lead candidate TRV120027 through a proof of concept Phase II trial.

The compound is in Phase I testing to treat acute heart failure. The dual-acting ligand inhibits angiotensin-mediated G protein signaling and stimulates beta arrestin signaling via the angiotensin II type I (ATI) receptor (AGTR1)...